Therapeutic effect of rosuvastatin combined with memantine hydrochloride on vascular dementia
10.3760/cma.j.issn.1008-6706.2019.17.014
- VernacularTitle: 瑞舒伐他汀联合盐酸美金刚治疗血管性痴呆的疗效观察
- Author:
Yuhua XU
1
;
Xiaoliang WANG
2
Author Information
1. Department of Neurology, the Hospital of Zhejiang Provincial Armed Police Force, Jiaxing, Zhejiang 314000, China
2. Department of Neurology, Haining Kanghua Hospital, Jiaxing, Zhejiang 314400, China
- Publication Type:Journal Article
- Keywords:
Dementia, vascular;
Oxidative stress;
Inflammation;
Comparative effectiveness research;
Rosuvastatin;
Memantine hydrochloride
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(17):2105-2109
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of rosuvastatin combined with memantine hydrochloride in the treatment of vascular dementia.
Methods:Sixty-six patients with vascular dementia admitted to the Hospital of Zhejiang Provincial Armed Police Force and Haining Kanghua Hospital from January 2016 to January 2018 were enrolled.According to the digital table, the patients were divided into the observation group and the control group, with 33 cases in each group.Both two groups were given routine treatment.The control group was treated with rosuvastatin, and the observation group was given rosuvastatin combined with memantine hydrochloride.Both two groups were treated for 12 weeks.The ADL score and MoCA score, oxidative stress index, inflammatory factor, cerebral kinetic index changes, clinical efficacy and adverse reactions after treatment were compared between the two groups.
Results:The therapeutic effect of the observation group was 87.88%(29/33), which was significantly higher than 63.64%(21/33) of the control group (χ2=5.280, P=0.022). After treatment, the ADL, MoCA, SOD levels, Vmax and BHI of the observation group were (41.26±5.37)points , (24.23±1.71)points, (112.27±15.35)μU/L, (65.15±11.75)cm/s, (0.79±0.36), respectively, which were higher than those of the control group [(36.19±4.07)points, (20.25±1.46)points, (93.84±12.76)μU/L, (59.15±11.74)cm/s, (0.58±0.26)], the differences were statistically significant (t=4.322, 10.168, 5.304, 2.075, 2.846, all P<0.05). The levels of MDA, HCy, TNF-α, IL-6 and IL-1β in the observation group were (6.37±1.05)μmol/L, (31.36±9.59)μmol/L, (184.15±15.12)ng/L, (229.85±27.69)ng/L, (127.64±17.86)ng/L, respectively, which were lower than those in the control group [(7.32±1.07)μmol/L, (42.27±11.34)μmol/L, (208.72±15.26)ng/L, (262.75±25.64)ng/L, (148.75±18.64)ng/L], the differences were statistically significant (t=3.640, 4.220, 6.570, 5.008, 4.698, all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).
Conclusion:The clinical efficacy of rosuvastatin combined with memantine hydrochloride in the treatment of patients with vascular dementia can significantly reduce oxidative stress and inflammatory response, improve cerebral hemodynamics and cognitive function, and improve patients’ quality of life.
